In a meta-analysis that combined three SGLT2 inhibitor CVOTs with five trials of GLP-1 RAs involving 42,920 patients, both GLP-1 RAs and SGLT2 inhibitors significantly reduced the risk of progression of kidney disease including macroalbuminuria compared with placebo, with hazard ratios of 0.82 (95% CI 0.75, 0.89) and 0.62 (95% CI 0.58, 0.67), respectively. Here, GLP1R is linked to kidney disorder.